NGC Update Service: September 14, 2015

September 14, 2015 New This Week Guideline Summaries American Academy of Neurology Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. European Respiratory Society An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. U.S. Preventive Services Task Force Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. This updates a previously published guideline summary. Announcements Conference News The Guidelines International Network (G-I-N) 12th annual conference will take place from October 7–10, 2015 in Amsterdam. The theme is "Engaging all stakeholders. Guidelines from a societal perspective." To register and book a pre-conference course, visit the G-I-N Conference Web site. Registration is now open for the Agency for Healthcare Research and Quality (AHRQ) 2015 Research Conference. It will be held October 4–6 at the Crystal Gateway Marriott Hotel and Convention Center in Crystal City, VA. The conference is titled "Producing Evidence and Engaging Partners to Improve Health Care." Visit the conference home page for more information. The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site. U.S. Food and Drug Administration (FDA) Advisories August 28, 2015: DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain: FDA is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. September 10, 2015: Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density: FDA has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density. To address these safety concerns, FDA added a new WARNING AND PRECAUTION and revised the ADVERSE REACTIONS section of the Invokana and Invokamet drug labels. Health Awareness Topics - September 2015 National Atrial Fibrillation Awareness Month (see related guidelines) National Sickle Cell Month (see related guidelines) National Traumatic Brain Injury Awareness Month (see related guidelines) Newborn Screening Awareness Month (see related guidelines) Ovarian Cancer Awareness Month (see related guidelines) Prostate Cancer Awareness Month (see related guidelines and guideline synthesis) Sepsis Awareness Month (see related guidelines) World Alzheimer's Month (see related guidelines) How to Participate Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines. Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC. Suggest a Guideline Synthesis Topic: We welcome your suggestions for guideline synthesis topics! NGC's Sister Resource Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).    How satisfied are you with this e-mail bulletin? Give Us Your Feedback Subscriber Services: Change Your Profile | Unsubscribe | Help Stay Connected: Contact Us | Social Media This email was sent to rssproject471@gmail.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364

Tweet

Postingan terkait:

— Monday, September 14, 2015 — Add Comment